Roy Baynes, Merck Research Laboratories CMO (file photo)

Mer­ck cross­es the fin­ish line with its next-gen pneu­mo­coc­cal vac­cine. Does it stand a chance against Pfiz­er's 20-va­lent shot?

Mer­ck has crossed the FDA fin­ish line with its next-gen­er­a­tion pneu­mo­coc­cal vac­cine, suc­ceed­ing in its ef­forts to one-up — or rather, two-up — Pfiz­er’s 13-strain shot, Pre­vnar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.